Flavia M Nelson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8545980/publications.pdf

Version: 2024-02-01

40 papers

1,763 citations

471509 17 h-index 36 g-index

41 all docs

41 docs citations

41 times ranked

2507 citing authors

#	Article	lF	CITATIONS
1	The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nature Reviews Neurology, 2016, 12, 714-722.	10.1	274
2	Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 165.	7.4	208
3	Improved Identification of Intracortical Lesions in Multiple Sclerosis with Phase-Sensitive Inversion Recovery in Combination with Fast Double Inversion Recovery MR Imaging. American Journal of Neuroradiology, 2007, 28, 1645-1649.	2.4	184
4	Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology, 2013, 73, 327-340.	5.3	182
5	Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1122-1129.	3.0	102
6	3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1214-1219.	3.0	101
7	Deep gray matter atrophy in multiple sclerosis: A tensor based morphometry. Journal of the Neurological Sciences, 2009, 282, 39-46.	0.6	77
8	Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Multiple Sclerosis Journal, 2013, 19, 1310-1319.	3.0	69
9	Caudate nuclei volume, diffusion tensor metrics, and T ₂ relaxation in healthy adults and relapsingâ€remitting multiple sclerosis patients: Implications for understanding gray matter degeneration. Journal of Magnetic Resonance Imaging, 2009, 29, 70-77.	3.4	63
10	Variable results after rituximab in neuromyelitis optica. Journal of the Neurological Sciences, 2012, 317, 103-105.	0.6	62
11	Diffusion-Tensor MR Imaging of Cortical Lesions in Multiple Sclerosis: Initial Findings. Radiology, 2008, 246, 880-886.	7.3	55
12	Imaging outcome measures of neuroprotection and repair in MS. Neurology, 2019, 92, 519-533.	1.1	53
13	Cervical Spinal Cord Lesions in Multiple Sclerosis: T1-weighted Inversion-Recovery MR Imaging with Phase-Sensitive Reconstruction. Radiology, 2008, 246, 258-264.	7.3	50
14	The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics. Multiple Sclerosis and Related Disorders, 2012, 1, 81-86.	2.0	40
15	Composite MRI scores improve correlation with EDSS in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1117-1125.	3.0	35
16	Chronic cerebrospinal venous insufficiency. Annals of Neurology, 2013, 73, 721-728.	5.3	24
17	Limbic Pathway Correlates of Cognitive Impairment in Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 37-42.	2.0	19
18	Is 3D MPRAGE better than the combination DIR/PSIR for cortical lesion detection at 3T MRI?. Multiple Sclerosis and Related Disorders, 2014, 3, 253-257.	2.0	16

#	Article	IF	CITATIONS
19	Optimal combination of FLAIR and T2â€weighted MRI for improved lesion contrast in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2016, 44, 1293-1300.	3.4	15
20	Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years. Multiple Sclerosis and Related Disorders, 2017, 18, 95-102.	2.0	15
21	Quantitative Limbic System Mapping of Main Cognitive Domains in Multiple Sclerosis. Frontiers in Neurology, 2018, 9, 132.	2.4	14
22	Standardizing Magnetic Resonance Imaging Protocols, Requisitions, and Reports in Multiple Sclerosis: An Update for Radiologist Based on 2017 Magnetic Resonance Imaging in Multiple Sclerosis and 2018 Consortium of Multiple Sclerosis Centers Consensus Guidelines. Journal of Computer Assisted Tomography, 2019, 43, 1-12.	0.9	14
23	Lateral ventricular cerebrospinal fluid diffusivity as a potential neuroimaging marker of brain temperature in multiple sclerosis: a hypothesis and implications. Magnetic Resonance Imaging, 2015, 33, 262-269.	1.8	12
24	Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessment. Multiple Sclerosis Journal, 2013, 19, 1499-1507.	3.0	10
25	Robustness of Brain Structural Networks Is Affected in Cognitively Impaired MS Patients. Frontiers in Neurology, 2020, 11, 606478.	2.4	10
26	Frontal aslant tracts as correlates of lexical retrieval in MS. Neurological Research, 2020, 42, 805-810.	1.3	10
27	Mapping the trajectory of the amygdalothalamic tract in the human brain. Journal of Neuroscience Research, 2018, 96, 1176-1185.	2.9	9
28	Novel fMRI working memory paradigm accurately detects cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 836-847.	3.0	8
29	Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731985575.	1.0	7
30	Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics. Neurotherapeutics, 2017, 14, 945-951.	4.4	6
31	Interleaved susceptibilityâ€weighted and FLAIR MRI for imaging lesionâ€penetrating veins in multiple sclerosis. Magnetic Resonance in Medicine, 2018, 80, 1132-1137.	3.0	6
32	Yakovlev's Basolateral Limbic Circuit in Multiple Sclerosis Related Cognitive Impairment. Journal of Neuroimaging, 2018, 28, 596-600.	2.0	6
33	Diffusion Tensor Imagingâ€Defined Sulcal Enlargement Is Related to Cognitive Impairment in Multiple Sclerosis. Journal of Neuroimaging, 2017, 27, 312-317.	2.0	3
34	Patientâ€specific 3D FLAIR for enhanced visualization of brain white matter lesions in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2017, 46, 557-564.	3.4	2
35	Myelinating Proteins in MS Are Linked to Volumetric Brain MRI Changes. Journal of Neuroimaging, 2019, 29, 400-405.	2.0	1
36	Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids May Extend above and below Pons and Is Associated with Other Autoimmune Diseases. Life, 2021, 11, 1120.	2.4	1

#	Article	IF	CITATIONS
37	Lack of response to rituximab therapy in patients with neuromyelitis optica: Response to Kim and Kim. Journal of the Neurological Sciences, 2012, 319, 172.	0.6	O
38	Diagnostic Evaluation. , 2021, , 45-58.		0
39	Symptomatic Management. , 2021, , 157-176.		O
40	Autologous Hematopoietic Stem Cell Transplantation for Relapsing-Remitting Multiple Sclerosis., 2021,, 375-385.		0